- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00428584
RNF and Betaseron® Tolerability Study (REFORMS)
August 1, 2013 updated by: EMD Serono
A Randomized, Multicenter, Two Arm, Open Label, Twelve Week Phase IIIb Study to Evaluate the Tolerability of Rebif (New Formulation) (IFN Beta-1a) and Betaseron (IFN Beta-1b) in IFN-naive Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Followed by a Single Arm, Eighty-two Week Minimum, Rebif (New Formulation) Only Safety Extension
To evaluate the tolerability of a new formulation of rebif and Betaseron in subjects with relapsing-remitting multiple sclerosis (RRMS) by comparing the mean change in injection site pain scores from pre-injection to 30 minutes post therapy administration.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
129
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Rockland, Massachusetts, United States, 02370
- EMD Serono Med Info
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject with diagnosis of RRMS according to McDonald criteria or Poser
- Subject is between 18 and 60 years old inclusive
- Subject is willing to follow study procedures
- Subject has given written informed consent
Female subjects must be neither pregnant nor breast-feeding and must lack childbearing potential, as defined by either:
- Being post-menopausal or surgically sterile, or
- Using a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study.
Exclusion Criteria:
- Subject has Clinically Isolated Syndrome (CIS), Primary Progressive MS, or Secondary Progressive MS without superimposed relapses.
- Subject has had any prior interferon beta therapy (either beta-1b or beta-1a) prior to study Day 1.
- Subject received any other approved disease modifying therapy for MS (glatiramer acetate) or any cytokine or anti-cytokine therapy within the 3 months prior to Study Day 1.
- Subject received immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone, teriflunomide, natalizumab, laquinimod, Campath and cladribine) within the 12 months prior to Study Day 1.
- Subject had prior use of Cladribine or has previously received total lymphoid irradiation.
- Subject has known allergy to natural or recombinant interferon or any other component of formulation excipient(s) of Rebif® or Betaseron®: Mannitol, Poloxamer 188, Methionine, Benzyl alcohol or Albumin (human).
- Use of any other injectable medications on a regular basis during the week prior to the screening period or during the screening or treatment periods. Receiving a single injection for treatment or prophylaxis of a condition unrelated to the subject's multiple sclerosis or the subject's Rebif® or Betaseron® therapy (e.g. receiving a influenza or pneumococcus vaccination) is acceptable.
- History of any chronic pain syndrome.
- Subject has any other disease apart from MS that could better explain the subjects signs and symptoms.
- Subject has complete transverse myelitis or bilateral optic neuritis.
- Subjects who used any investigational drug or experimental procedure within 12 weeks prior to visit 1.
- Subject has inadequate liver function, defined by a total bilirubin, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) or alkaline phosphatase > 2.5 times the upper limit of the normal values.
- Subject has inadequate bone marrow reserve, defined as a white blood cell count less than 0.5 x lower limit of normal.
- Subject suffers from current autoimmune disease (other than RRMS).
- Subject suffers from major medical or psychiatric illness that in the opinion of the investigator creates undue risk to the subject or could affect compliance with the study protocol
- Subject is pregnant or attempting to conceive
- Visual or physical impairment that precludes completion of diaries and questionnaires.
- Subject received oral or systemic corticosteroids or ACTH within 30 days of visit 1.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
interferon beta-1a
|
New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
|
Active Comparator: 2
interferon beta-1b
|
Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Visual Analog Scale (VAS) of Patient Reported Pain: Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 30 Minutes Post-injection Timepoints
Time Frame: From pre-injection to 30 minutes post injection of the VAS pain scores across the first 21 injections of full dose therapy of a new formulation of rebif and Betaseron
|
Subject reported perception of pain on the VAS where the slash drawn by the patient represents pain of increasing intensity from 0 (no pain) to 100 (worse possible pain), measured in millimeters.
Mean VAS of 21 injections for each patient at pre-injection compared to mean VAS of 21 injections for each patient 30 minutes post-injection
|
From pre-injection to 30 minutes post injection of the VAS pain scores across the first 21 injections of full dose therapy of a new formulation of rebif and Betaseron
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and Immediately After Injection Timepoints
Time Frame: Pre-Injection to Immediately after Injection
|
A visual analog scale (VAS) ranging from 0 to 100 mm on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm) was used.
Mean VAS of 21 injections for each patient at pre-injection compared to mean VAS of 21 injections for each patient immediately after injection.
|
Pre-Injection to Immediately after Injection
|
Change in Mean VAS for the 21 Full-dose Injections at Pre-injection and 10 Minutes Post-injection Timepoints
Time Frame: Pre-injection to 10 minutes post-injection
|
A visual analog scale (VAS) ranging from 0 to 100 mm on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm) was used.
Mean VAS of 21 injections for each patient at pre-injection compared to mean VAS of 21 injections for each patient 10 minutes post injection.
|
Pre-injection to 10 minutes post-injection
|
Number of Pain Free Patients at 30 Minutes Post-injection
Time Frame: 30 minutes post injection
|
A visual analog scale (VAS) ranging from 0 to 100 mm on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm) was used. Pain-free was defined as a VAS score of 0 for all 21 full-dose injections for the Intent-to-Treat (ITT) population. |
30 minutes post injection
|
Diameter of Injection Site Redness
Time Frame: 1-72 hours post injection over the first 12 weeks including the titration period
|
Blinded assessment of mean change in diameter of redness (in mm) at an injection site following an injection
|
1-72 hours post injection over the first 12 weeks including the titration period
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Secondary Outcome - Extension Phase: Change in Mean (mm) VAS for Pre-injection and Immediately After Injection Timepoints
Time Frame: Pre-injection and immediately after injection
|
A visual analog scale (VAS) ranging from 0 to 100 mm on which subjects rate pain from no pain (0 mm) to worst possible pain (100 mm) was used.
Mean VAS of 21 injections for each patient at pre-injection compared to mean VAS of 21 injections for each patient immediately after injection.
|
Pre-injection and immediately after injection
|
Secondary Outcome - Extension Phase: Change in Mean VAS at Pre-injection and 10 Minutes Post Injection
Time Frame: Pre-injection and 10 minutes post injection
|
Pre-injection and 10 minutes post injection
|
|
Secondary Outcome - Extension Phase: Number of Pain Free Patients at 30 Minutes Post Injection
Time Frame: Pain free patients at 30 minutes post injection
|
Pain free patients at 30 minutes post injection
|
|
Secondary Outcome - Extension Phase: Diameter in Injection Site Redness
Time Frame: 1 to 72 hours post injection
|
1 to 72 hours post injection
|
|
Primary Outcome - Extension Phase: Visual Analog Scale (VAS) of Patients Reported Pain; Change in Mean VAS at Pre-injection and 30 Minutes Post Injection
Time Frame: Pre-injection and 30 minutes post injection
|
Pre-injection and 30 minutes post injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
November 1, 2007
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
January 29, 2007
First Submitted That Met QC Criteria
January 29, 2007
First Posted (Estimate)
January 30, 2007
Study Record Updates
Last Update Posted (Estimate)
August 7, 2013
Last Update Submitted That Met QC Criteria
August 1, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Autoimmune Diseases
- Multiple Sclerosis
- Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Interferons
- Interferon beta-1a
- Interferon-beta
Other Study ID Numbers
- 27133
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Remitting Multiple Sclerosis (RRMS)
-
BiogenRecruiting
-
BayerCompletedRelapsing Remitting Multiple Sclerosis (RRMS)China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
-
Bristol-Myers SquibbRecruitingRelapsing-remitting Multiple Sclerosis (RRMS)Spain
-
BiogenCompletedRelapsing-Remitting Multiple Sclerosis (RRMS)Italy
-
Polpharma Biologics S.A.CompletedRelapsing-Remitting Multiple Sclerosis (RRMS)Belarus, Ukraine, Georgia, Croatia, Moldova, Republic of, Poland, Serbia
-
CinnagenCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Iran, Islamic Republic of
-
Germans Trias i Pujol HospitalMinisterio de Sanidad, Servicios Sociales e IgualdadCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Spain
-
Novartis PharmaceuticalsTerminatedRelapsing Remitting Multiple Sclerosis (RRMS)Germany, Spain, Australia, Israel, Switzerland, Italy, Austria, Greece, Hungary, Czech Republic, Finland
-
Merck KGaA, Darmstadt, GermanySmerud Medical Research International AS; Merck Serono NorwayCompletedRelapsing Remitting Multiple Sclerosis (RRMS)Norway
-
Novartis PharmaceuticalsCompletedRelapsing Remitting Multiple Sclerosis RRMSGermany, Switzerland
Clinical Trials on New Formulation of rebif - human interferon beta-1a
-
Merck KGaA, Darmstadt, GermanyMerck Serono Australia Pty LtdCompleted
-
EMD SeronoCompletedRelapsing Multiple SclerosisUnited States
-
Merck KGaA, Darmstadt, GermanyCompletedMultiple Sclerosis, Relapsing-Remitting
-
Merck KGaA, Darmstadt, GermanyCompletedRelapsing-Remitting Multiple SclerosisGermany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
-
Merck KGaA, Darmstadt, GermanyMerck B.V., Netherlands; Merck A.E., Greece; Merck OY, Finland; Merck A.B., Sweden and other collaboratorsCompletedMultiple Sclerosis, Relapsing RemittingGreece
-
Merck KGaA, Darmstadt, GermanyMerck spol.s.r.o., Czech RepublicCompletedMultiple Sclerosis, Relapsing-RemittingCzech Republic
-
Merck KGaA, Darmstadt, GermanyGesellschaft für Therapieforschung mbHCompleted
-
Merck KGaA, Darmstadt, GermanyGesellschaft für Therapieforschung mbHCompleted
-
Merck KGaA, Darmstadt, GermanyCompletedRelapsing Remitting Multiple Sclerosis
-
BiocadCompletedMultiple SclerosisRussian Federation